Evidence map›Paper›PMID 37831679›Full record

ArticlePloS one2023

The Burden of Disease due to COVID-19 (BoCO-19): A study protocol for a secondary analysis of surveillance data in Southern and Eastern Europe, and Central Asia.

Caoimhe Cawley, Jonila Gabrani, Aleksandar Stevanović, Rakhat Aidaraliev, Mehtap Çakmak Barsbay, Seila Cilovic Lagarija, Kairat Davletov, Tolkun Djamangulova, Natalya Glushkova, Matthias An der Heiden and 15 more

Abstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Caoimhe CawleyDepartment2: Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, Germany.
Jonila GabraniNational Association of Public Health, Tirana, Albania.
Aleksandar StevanovićInstitute of Social Medicine, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.ORCID 0000-0003-4759-075X
Rakhat AidaralievPublic Association "Healthy Future", Bishkek, Kyrgyzstan.
Mehtap Çakmak BarsbayFaculty of Economics and Administrative Sciences, Department of Health Management, Ankara Hacı Bayram Veli University, Ankara, Türkiye.ORCID 0000-0001-7609-6254
Seila Cilovic LagarijaInstitute of Public Health of the Federation of Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina.
Kairat DavletovAsfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
Tolkun DjamangulovaPublic Association "Healthy Future", Bishkek, Kyrgyzstan.
Natalya GlushkovaFaculty of Medicine, Al-Farabi Kazakhs National University, Almaty, Kazakhstan.ORCID 0000-0003-1400-8436
Matthias An der HeidenDepartment 3: Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Pranvera Kaçaniku-GungaNational Institute of Public Health of Kosovo, Pristina, Kosovo.
Maia KereselidzeNational Center for Disease Control & Public Health, Tbilisi, Georgia.
Besfort KryeziuNational Institute of Public Health of Kosovo, Pristina, Kosovo.ORCID 0000-0002-9529-0770
Khorolsuren LkhagvasurenMongolian National University of Medical Sciences, School of Public Health, Ulaanbaatar, Mongolia.
Samir MehdiyevPublic health and reforms center, Ministry of Health, Baku, Azerbaijan.
Dariia OharovaPublic Health Center of the Ministry of Health of Ukraine, Kyiv, Ukraine.
Diloram SadikkhodjayevaTashkent Institute of Postgraduate Medical Education, Tashkent, Uzbekistan.
Milena Santric MilicevicInstitute of Social Medicine, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Milica StanisicInstitute of Public Health of Montenegro, Podgorica, Montenegro.
Stela StojisavljevicPublic Health Institute of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina.
Gulcan TecirliMinistry of Health, Ankara, Türkiye.
Natasa TerzicInstitute of Public Health of Montenegro, Podgorica, Montenegro.
Annelene WenglerDepartment2: Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, Germany.
Alexander RommelDepartment2: Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, Germany.ORCID 0000-0001-7253-0535
BoCO-19 Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe COVID-19 pandemic has had an extensive impact on public health worldwide. However, in many countries burden of disease indicators for COVID-19 have not yet been calculated or used for monitoring. The present study protocol describes an approach developed in the project "The Burden of Disease due to COVID-19. Towards a harmonization of population health metrics for the surveillance of dynamic outbreaks" (BoCO-19). The process of data collection and aggregation across 14 different countries and sub-national regions in Southern and Eastern Europe and Central Asia is described, as well as the methodological approaches used. MATERIALS AND

methodsThe study implemented in BoCO-19 is a secondary data analysis, using information from national surveillance systems as part of mandatory reporting on notifiable diseases. A customized data collection template is used to gather aggregated data on population size as well as COVID-19 cases and deaths. Years of life lost (YLL), as one component of the number of Disability Adjusted Life Years (DALY), are calculated as described in a recently proposed COVID-19 disease model (the 'Burden-EU' model) for the calculation of DALY. All-cause mortality data are collected for excess mortality sensitivity analyses. For the calculation of Years lived with disability (YLD), the Burden-EU model is adapted based on recent evidence. Because Covid-19 cases vary in terms of disease severity, the possibility and suitability of applying a uniform severity distribution of cases across all countries and sub-national regions will be explored. An approach recently developed for the Global Burden of Disease Study, that considers post-acute consequences of COVID-19, is likely to be adopted. Findings will be compared to explore the quality and usability of the existing data, to identify trends across age-groups and sexes and to formulate recommendations concerning potential improvements in data availability and quality. DISCUSSION: BoCO-19 serves as a collaborative platform in order to build international capacity for the calculation of burden of disease indicators, and to support national experts in the analysis and interpretation of country-specific data, including their strengths and weaknesses. Challenges include inherent differences in data collection and reporting systems between countries, as well as assumptions that have to be made during the calculation process.

Indexed as

COVID-19PandemicsAsia, CentralCost of IllnessEurope, EasternHumansQuality-Adjusted Life Years

Identifiers

PMID37831679
PMCPMC10575506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.